SCHEMBL2778464

SCHEMBL2778464

COc1cccc(OC)c1CN=C(N)Nc1ncccc1C#N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
HPGD P15428 7/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
PLAU P00749 1/20 0.38
CLK2 P49760 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
CDK9 P50750 1/20 0.38
CDK5 Q00535 1/20 0.38
DYRK1A Q13627 1/20 0.38
TAOK1 Q7L7X3 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
ATP4A P20648 1/20 0.37
ATP4B P51164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2779935 0.83 PLAU (0.40) NPC1RAB9APLAUCLK2GSK3A
SCHEMBL2782169 0.83 NPC1 (0.45) NPC1RAB9AHPGDCYP1A2CYP2D6
SCHEMBL2778479 0.78 HCRTR1 (0.44) CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4
SCHEMBL2778460 0.76 NPC1 (0.48) NPC1RAB9AHPGDCYP1A2CYP2D6
SCHEMBL2780629 0.76 HCRTR2 (0.44) CYP2C19ATP4AATP4B
SCHEMBL2379472 0.75 P2RX7 (0.40) ATP4AATP4BALDH1A1SMN1; SMN2KDM4E
SCHEMBL2782766 0.75 ATP4A (0.41) NPC1RAB9ACLK2GSK3AGSK3B
Acetic Acid SCHEMBL2782162 0.72 NPC1 (0.44) NPC1RAB9AHPGDCYP1A2CYP2D6
SCHEMBL2801672 0.71 HPGD (0.47) NPC1RAB9AHPGDCYP1A2CYP2D6
SCHEMBL2782907 0.70 CLK2 (0.53) NPC1RAB9APLAUCLK2GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296697-B2 Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors ABBOTT LABORATORIES (US) 2016-03-29 US claimed
US-9296697-B2 Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors ABBOTT LABORATORIES (US) 2016-03-29 US disclosed
US-20100184787-A1 Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184787-A1 Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors HTR5A, HTR2C, HTR1E NPC1 2234/4885RAB9A 1031/4885HPGD 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.